Elevated lipoprotein (a) in middle-aged Polish population: preliminary data on genetic background

Konieczyńska, Małgorzata; Nowak, Karol; Pudło, Joanna; Zasada, Monika; Tlałka, Magdalena; Wypasek, Ewa; Zalewski, Jarosław; Polak, Maciej; Undas, Anetta

doi:10.33963/v.kp.97660

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike in other studies in our population, we did not find a correlation of increased Lp(a) concentration with gender or LDL-C [35,36]. Perhaps the lack of influence of these parameters resulted from the selection of the studied population -very high cardiovascular risk, because most of the research results come from groups with lower cardiovascular risk, and even often from the general and younger population [34].…”

Section: P R E P R I N Tcontrasting

confidence: 90%

“…A recently published Polish registry of 800 healthy people limited to those aged between 40 and 65 from the Małopolska Region also found significantly lower rates of atherosclerosis risk factors (including hypertension and total cholesterol) and inflammatory markers. Additionally, in patients with Lp(a) levels >50 mg/dl (125 nmol/l) (there were 17.8% of such patients similarly to our cohort) [34].…”

Section: P R E P R I N Tsupporting

confidence: 57%

See 1 more Smart Citation

Lipoprotein(a) and its impact on cardiovascular disease – the Polish perspective: design and first results of the Zabrze-Lipoprotein(a) Registry

Dyrbuś,

Mędrala,

Konsek

et al. 2024

Arch Med Sci

View full text Add to dashboard Cite

IntroductionLipoprotein(a) is an independent risk factor for ASCVD. An Lp(a) concentration >30 mg/dl may cause faster atherosclerosis, making it an essential residual cardiovascular risk factor. It is necessary to characterize the patients at risk for ASCVD with high Lp(a) levels.Material and methodsThe Zabrze-Lipoprotein(a) Registry was founded on the basis of data from 2,001 consecutive patients with very high cardiovascular risk treated in a tertiary hospital.ResultsThe mean age of patients was 66.4 years (females 37.1%). The median Lp(a) concentration in the entire population was 6.6 mg/dl (16.5 nmol/l) (mean 14.3±19.4 mg/dl). 540 (27%) patients had elevated Lp(a) levels above 30 mg/dl (75 nmol/l); they were significantly older (68.8 vs 66.3 years; p=0.04), had significantly lower haemoglobin and hematocrit, and higher platelet count and levels of NT-proBNP and CRP. The prevalence of elevated Lp(a) >30 mg/dL (75 nmol/l) concentrations was very high in patients with a chronic coronary syndrome (CCS) (52.2% [282/540] vs. 41.5% [607/1461]; p<0.001), in patients undergoing PCI during hospitalization (23.9 vs.19%; p=0.01), and in patients with previous MI (20.6 % vs. 14.9%; p=0.0022). In the multivariable analysis, the independent predictors of elevated Lp(a) >30 mg/dl (75 nmol/l) were only lower Hb values (OR 0.925; 95%CI: 0.874–0.978; p=0.006), and higher platelet count (1.002; 95%CI: 1.000-1.003; p<0.02).Conclusions27% of patients with very high cardiovascular risk in Poland have an additional risk related to an increase in Lp(a) level with even every second patient with CCS. Two factors were significantly related to elevated Lp(a) levels—lower Hb values and higher platelet count.

show abstract

Section: P R E P R I N Tcontrasting

confidence: 90%

Section: P R E P R I N Tsupporting

confidence: 57%